NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, announces that its chief medical officer, Roger Waltzman, M.D., M.B.A. will be moderating a panel at the annual CMO360 Summit, being held April 7-8 in Boston. Dr. Waltzman’s panel, titled “Ensuring Effective and Efficient Trials... Read More

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc . (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of Decoy20. As announced in last week’s earnings release, the Company has now enrolled more than 20 patients... Read More

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that it has advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a... Read More

Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20 Pharmacodynamic immune activation biomarker and pharmacokinetics profiles in initial data sets appear to meet or exceed initial expectations Early signs of potential benefit emerge with some patients demonstrating Stable Disease NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics,... Read More

Meet with Indaptus Therapeutics’ CEO Jeffrey Meckler Register at INDP-KEYS.TribePublic.com NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc . (NASDAQ: INDP) announces that Indaptus’ CEO, Jeffrey Meckler, will present at Tribe Public’s Webinar Presentation and Q&A Event titled “Keys To The Kingdom:... Read More

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announced today that it has secured new patent approvals in China, Japan and Israel for its Decoy platform. These patents cover the use of Decoy bacteria compositions for preventing or treating Hepatitis B virus (HBV) and... Read More

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that Michael Newman, Founder and Chief Scientific Officer, will present at the 10th Annual Innate Killer Summit, taking place from March 3-5, 2025, in San Diego, California. Dr. Newman will deliver a scientific... Read More

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the Company has received Clinical Trial Authorization from Health Canada to initiate its clinical trial for its lead asset, Decoy20. This approval will allow the Company to expand its ongoing... Read More

NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase agreements with investors for the issuance and sale in a private placement priced at-the-market under Nasdaq rules of an aggregate of 2,109,383 of its... Read More

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today highlights its accomplishments in 2024 and outlines the Company’s strategic goals for the year ahead. Advancing Decoy20 in Clinical Trials 2024 was a year of meaningful progress for Indaptus’ lead... Read More

NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase agreements with investors, including an officer of Indaptus, for the issuance and sale of an aggregate of 1,817,017 of its shares of common stock. In a... Read More

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the third quarter ended September 30, 2024, and provided a corporate update. Jeffrey Meckler, Indaptus Therapeutics’ Chief Executive Officer, commented, “The... Read More

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announced today that Dr. Michael Newman, Founder and Chief Scientific Officer, has published his groundbreaking research in the peer-reviewed journal, Frontiers in Immunology . The article, titled... Read More

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces compelling safety, pharmacokinetics, and biomarker data on its lead compound, Decoy20, at the Society for Immunotherapy of Cancer (SITC) 2024 annual meeting. The data derive from two... Read More

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present at two upcoming investor conferences: BioFuture 2024 The conference is being held on October 28 – 30, 2024 at Cure by Deerfield in New York City. Presentation Date: Monday, October 28, 2024 Time: 3:30 PM ET Track: 12 - B (12th Floor) Mr. Meckler will be... Read More

Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration systemic immune stimulator Decoy20 expected to start in 2025 Indaptus Therapeutics Management will hold a conference call on October 22, 2024 at 4:30PM ET to discuss the agreement and future plans NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a... Read More

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, provides an update regarding key clinical advancements in its Phase 1 trial of lead drug candidate Decoy20. The Safety Review Committee examined weekly administration data at the lower Decoy20 dose... Read More

NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that its Founder and Chief Scientific Officer, Dr. Michael Newman, will participate as a panelist in an upcoming webinar hosted by Lumanity. The webinar, titled "Adapting to Immuno-Oncology’s R&D Challenges:... Read More

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group. The summit is being held virtually on October 15 – 17, 2024. Event: Fireside Chat at 2024... Read More

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, provides an update regarding key clinical advancements. The independent Safety Review Committee overseeing the Company’s Phase 1 clinical trial convened in August to review the safety data at the... Read More

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26 th Annual Global Investment Conference. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel. Presentation Date: September 9, 2024 Time: Available on-demand starting at 7:00 AM... Read More

NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update. Jeffrey Meckler, Indaptus Therapeutics’ Chief Executive Officer, commented, “During... Read More

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase agreements with investors, including an officer of Indaptus, for the issuance and sale of an aggregate of 1,643,837 of its shares of common stock. In a... Read More

Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s “Pulse-Prime” hypothesis Dr. Newman also named Chair of the Summit NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc , (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its founder and Chief Scientific... Read More

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc , (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Chief Medical Officer, Roger Waltzman, M.D., will present an update on the Company’s lead product candidate, Decoy20, at the 7th Annual Next-Gen Immuno-Oncology Conference in Boston on June 20-21,... Read More

Latest data from first and second cohorts support Company’s 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile Poster Presented at American Society of Clinical Oncology Annual Meeting NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral... Read More

NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc . (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces today that Jeffrey Meckler, Chief Executive Officer, and Roger Waltzman, M.D., M.B.A., Chief Medical Officer, will present a corporate overview at the Jefferies Global Healthcare Conference. The conference is being... Read More

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc , (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces data from a poster being presented at the American Society of Clinical Oncology Annual Meeting 2024 on June 1. The conference will be held in Chicago at McCormick Place from May 31-June 4, 2024 where full data... Read More

First-in-human trial confirms “Pulse-Prime” hypothesis targeting stimulation of innate and adaptive immune systems Investigational package of broad immune agonists derived from Gram-negative bacteria which induces dozens of cytokines/chemokines that are quickly cleared from the body Identification of tolerable single dose in Phase 1a, recommended for multi-dosing, will be presented at ASCO NEW YORK, May 22, 2024 (GLOBE... Read More

NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update. Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, “We continue to make... Read More

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc , (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, was proud to unveil its poster at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego on Wednesday, April 10 th . The poster details mechanism of action data that demonstrates the... Read More

NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces today that its CEO, Jeffrey Meckler will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference. The conference is being held on April 3 - 4, 2024 at Cooley Law, 55 Hudson Yards, New York,... Read More

Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows activity in M1 macrophages, natural killer cells, dendritic cells, Th1 CD4, and CD8 T cells NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc , (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and... Read More

“Fully Engaging The Human Immune System To Cure Disease,” Featuring CEO, Jeffrey Meckler Registration now open at INDPMarch2024.TribePublic.com NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces that its CEO, Jeffrey Meckler, will present and participate in an open... Read More

Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiating Multi-Dosing for patients with solid tumors NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate update. Jeffrey Meckler, Chief Executive Officer of... Read More

Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort Single dose cohort data expected to be published at a scientific conference in 2024 NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc , (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and... Read More

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announced today that Jeffrey A. Meckler, Chief Executive Officer, and Nir Sassi, Chief Financial Officer, will present a corporate update at the 2024 BIO CEO & Investor Conference. The conference is being held on February 26 –... Read More

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, is pleased to announce the launch of a new social media initiative to provide education and updates about the company. Recognizing the importance of engaging with all stakeholders, Indaptus will generate content on a variety of... Read More

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to generate stabilized packages of immune agonists to activate both innate (immediate) and adaptive (learned) cellular immune pathways, announces that the European Patent Office (EPO) has informed the company that it will grant a... Read More

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. “We continue to be encouraged by early results from our first cohort of patients in the INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors. As we recently reported and presented... Read More

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to generate a stabilized package of immune agonists to activate both innate (immediate) and adaptive (learned) cellular immune pathways, announces interim data from the first cohort of four patients in the Phase 1 INDP-D101 trial of its... Read More

Poster to be presented at 38 th Annual Meeting of the Society for Immunotherapy of Cancer on November 4, 2023 NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announces it will be presenting interim data from the first cohort of four patients in the Phase 1 INDP-D101 trial of its lead compound, Decoy20. The interim data, released today in abstract form, demonstrated that as of August 31,... Read More

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the LD Micro Main Event XVI. The conference is being held on October 3 – 5, 2023 at the Luxe Sunset Boulevard Hotel in Los Angeles. Event: LD Micro Main Event XVI Presentation Date: Tuesday, October 3 Time: 12:30pm PT (Track 3) Webcast... Read More

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) announces that Indaptus’ CEO, Jeffrey Meckler will present at Tribe Public’s Webinar Presentation and Q&A Event titled “ Immunotherapy Reimagined." The Event is scheduled to begin at 8:30am pacific/11:30am eastern on Friday, September 29,... Read More

NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) announces dosing of the first patient in the second cohort of patients to receive a single dose of Decoy20 in the INDP-D101 trial. This cohort dose is a dose reduction from the previous cohort based on the significant pharmacodynamic effect seen with the first cohort and anticipated optimal Decoy20 safety... Read More

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25 th Annual Global Investment Conference. The conference is being held on September 11 – 13, 2023 at the Lotte New York Palace Hotel. Presentation Date: September 13, 2023 Time: 8:30am ET Webcast Link:... Read More

NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. “We have recently announced the completion of the first cohort of patients in our INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors and receipt of authorization from the Safety... Read More

Cohort 1 patients exhibited a significant immune response consistent with the mechanism of action Safety Review Committee approved continuation to the next cohort of patients NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced completion of the first cohort of patients who received a single dose in Part 1 of its INDP-D101 trial of Decoy20 and... Read More

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announces the appointment of Roger Waltzman, M.D. as its Chief Medical Officer, effective August 7, 2023. Jeffrey Meckler, Indaptus’ CEO commented, “Roger’s deep experience in drug development, particularly in the field of... Read More

NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced today that CEO Jeffrey A. Meckler will participate in the Maxim Group Virtual Healthcare Conference presented by Maxim Group and hosted by M-Vest. The conference is being held virtually on June 20 – 22, 2023. Mr. Meckler will... Read More

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced today that CEO Jeffrey A. Meckler will present a corporate overview at the Jefferies Healthcare Conference 2023. The conference is being held at the Marriott Marquis in NYC. Presentation Date: Friday, June 9 Time: 8:00 – 8:25am... Read More

NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. “Following the dosing and completion of our first patient in the first cohort of our INDP-D101 trial of Decoy20 for the treatment of solid tumors, we continue the screening and enrollment process to... Read More

NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that it has received notice of allowance for a disease agnostic, composition and method of preparing patent (#429419) from Intellectual Property India for its Decoy immunotherapy platform. India marks the 32 nd country in... Read More

NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the Company’s Chief Scientific Officer, Michael Newman, Ph.D., has been named chair for two of the three days of the 4 th STING & TLR-Targeting Therapies Summit to be held in Boston on May... Read More

NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that CEO Jeffrey A. Meckler will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023. The conference is being held on April 25 – 27, 2023 at the Horseshoe Hotel & Casino (formerly Bally’s) in Las... Read More

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the Company’s Decoy anti-tumor platform. The poster, titled, “ A... Read More

NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces it has received a patent allowance on Application #1120150158323 from the National Institute of Industrial Property of Brazil for its Decoy immunotherapy platform. The allowed patent includes a disease agnostic... Read More

NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that it will participate at the Investor Summit Conference being held virtually on March 29, 2023. Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview on March 29, 2023 at 10:00am ET. Mr.... Read More

NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a corporate update. “With the initiation of our INDP-D101 trial at the end of December 2022 and the subsequent dosing of our first patient in the first cohort, we are well underway in our Phase 1... Read More

NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that the American Association for Cancer Research (AACR) has accepted an abstract on its Decoy anti-tumor platform for its annual scientific conference on April 14-19, 2023 in Orlando. The... Read More

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that Atlanta, Ga.-based Emory Winship Cancer Institute (“Emory”) has become a new clinical trial site for INDP-D101. INDP-D101 is the Company’s first-in-human, open label, dose escalation... Read More

NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the dosing of the first subject in INDP-D101. INDP-D101 is the Company’s first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound... Read More

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces it has named Robert Martell, M.D., Ph.D. to its Board of Directors. Having been in the pharmaceutical industry for more than 20 years, Dr. Martell currently serves as Head of Research and... Read More

NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the addition of Morristown Medical Center, part of the Atlantic Health System, as a new clinical trial site for INDP-D101. INDP-D101 is the Company’s first-in-human, open label, dose... Read More

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the initiation of INDP-D101, its first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound Decoy20 in patients with... Read More